Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced the continuation of work within its Anti-Infective Research (AIR) Unit at the Murdoch Children’s Research Institute (MCRI), to streamline its ongoing preclinical programs while investigating new indications for future clinical trials.

In 2023, Recce established its dedicated AIR Unit led by researcher Sohinee Sarkar, Ph.D., within MCRI’s state-of-the-art research facilities, underscoring the commitment of both organizations to drive innovation for anti-infective therapeutics.

This existing partnership has been instrumental in providing significant results in ongoing preclinical studies of Recce’s lead candidate, RECCE 327, against a broad range of life-threatening infectious pathogens such as Escherichia coli, which can lead to urinary tract infections, and if left untreated, urosepsis, Mycobacterium abscessus, Streptococcus pneumoniae and Neisseria gonorrhoeae, a priority pathogen on the World Health Organization’s list of bacteria that poses the greatest threat to human health.

“The threat of antibiotic resistance is greater now than ever, and commercial-academic partnerships are crucial to advance antibiotic discovery,” said Professor Andrew Steer, Theme Director of Infection, Immunity, and Global Health at MCRI. “The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance.”

The collaboration between Recce’s AIR Unit and MCRI exemplifies the power of partnership in driving medical breakthroughs. As both organizations work together to advance anti-infective research, they remain committed to improving patient outcomes and addressing global health challenges.

James Graham, Chief Executive Officer of Recce Pharmaceuticals, added, “Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research. The synergy between our organizations will undoubtedly lead to ground-breaking discoveries that have the potential to transform the landscape of infectious disease treatment."

About Murdoch Children’s Research Institute
Murdoch Children's Research Institute is the largest child health research institute in Australia committed to making discoveries and developing treatments to improve child and adolescent health in Australia and around the world. They are pioneering new treatments, trialling better vaccines and improving ways of diagnosing and helping sick babies, children and adolescents. It is one of the only research institutes in Australia to offer genetic testing to find answers for families of children with previously undiagnosed conditions.